Schering-Plough Research Institute is the pharmaceutical research arm of Schering-Plough Corporation. Headquartered in the recently constructed, state-of-the-art Drug Discovery Facility in Kenilworth, N.J., our more than 2,700 employees around the world are pursuing new leads in targeted therapeutic areas and assembling a product pipeline that will address pressing health care issues today and well into the future. Understanding the mechanisms of diseases and applying that new-found knowledge to developing innovative drugs for improvements in human health represents the foundation of Using Science for Human Advantage. The cutting-edge of pharmacological science is where you will find Schering-Plough Research Institute.

 

Investing in Research

Built on a strategy of "Growth Through Research" -- the cornerstone of our business philosophy since the 1940s -- and a belief that Schering-Plough's future depends on the creativity and success of our scientists, we continue to demonstrate a resolute commitment to research:

• Annual increases in R&D spending average about 14 percent, one of the highest levels in the pharmaceutical industry.

• Over the past 10 years alone, we have invested more than $4.5 billion in research, the majority of which has been conducted in our home state of New Jersey.

• In 1996, we spent $723 million on R&D, a fourth of which was directed to biotechnology.

• In 1997, our R&D spending is expected to exceed $750 million.

Scientists and Researchers

The force driving Schering-Plough Research Institute (SPRI) is a team of creative, talented scientists and researchers worldwide who are working together to discover and develop new medications that can extend or enhance life. Critical components of Schering-Plough's research and development success include:

• An atmosphere of "shared discovery" in which both individual initiative and group collaboration are encouraged and rewarded.

• Interdisciplinary therapeutic project teams that oversee the drug development process, from discovery through marketing.

	SPRI offers career opportunities for scientists at all degree levels in such disciplines as:
	Bioinformatics Biology Biostatistics Biotechnology Chemistry Clinical Research Drug Safety and Metabolism Genomics Pharmaceutical Sciences Process Engineering

Working within our targeted therapeutic areas -- allergic and inflammatory disorders, infectious and cardiovascular diseases, oncology and central nervous system diseases -- SPRI scientists are exploiting the latest technologies to produce a host of novel therapeutic agents for future development. At the same time, through the options of licensing and co-development programs, SPRI maintains the flexibility to pursue scientific advances in other areas.

As leading scientists in their respective disciplines, SPRI researchers:

• Have received numerous honors and tributes from outside organizations.

• Have presented scientific papers at major international symposia.

• Are frequently elected Fellows of such distinguished institutions as the Institute of Medicine, the National Academy for Microbiology and the Royal College of Physicians.

• Hold numerous academic appointments and academic advisory positions.

• Assume leadership roles in such prominent technical and medical organizations as the National Institutes of Health.

In addition, Schering-Plough recognizes the outstanding contributions of our scientists and researchers through various reward and recognition programs, including President's Awards conferred for exceptional discovery and development efforts.

A summer paid-internship program at SPRI allows undergraduate students to work with our scientists in a wide variety of research activities.

Research Pipeline

Discovering and developing new pharmaceuticals is the primary focus of SPRI. To this end, Schering-Plough has built the most productive research pipeline in its history through individual initiative as well as collaborative teamwork. Using the latest tools of chemical synthesis, molecular biology, combinatorial chemistry, X-ray crystallography and biotechnology, our global team of scientists is pursuing new leads in our targeted therapeutic areas.

The pipeline includes:

• Several formulations of mometasone furoate, a potent anti-inflammatory steroid for bronchial asthma and rhinitis.

• A genetically engineered antibody -- identified through collaborative research with Celltech Group plc -- that shows potential in treating chronic asthma and allergies.

• New applications of INTRON A (alpha interferon), an anticancer and antiviral agent, already approved in more than 82 countries for over 20 indications. It is currently being studied as a single therapy and in combination with other drugs for such diseases as bladder cancer, chronic myelogenous leukemia, multiple myeloma, non-Hodgkin's lymphoma, ovarian cancer and hepatitis B and C.

• EULEXIN (flutamide), an oral treatment approved in the U.S. and marketed in numerous countries for advanced prostate cancer. It is currently awaiting approval in Europe for use in earlier-stage prostate cancer.

• p53 gene, a tumor suppressor gene -- in development at our Canji Research Institute -- that produces apoptosis (programmed cell death) in tumors.

• Such promising lymphokines as interleukin-4, being studied for
  non-small-cell lung cancer; interleukin-10, being explored for Crohn's disease, ulcerative colitis and rheumatoid arthritis; and interleukin-11, a blood cell growth factor under investigation with Genetics Institute, Inc.

• Temozolomide, a promising anticancer compound -- licensed from Cancer Research Campaign Technology Ltd. -- for treating malignant gliomas (brain tumors) and malignant melanoma.

• FARESTON (toremifene), an anti-estrogen -- licensed from Orion Corporation and awaiting FDA marketing clearance -- for treating advanced breast cancer.

• A cholesterol absorption inhibitor for treating atherosclerosis.

• INTEGRILIN, a novel cardiovascular agent -- being studied through a co-marketing agreement with COR Therapeutics -- for treating unstable angina and acute myocardial infarction.

• Two promising compounds identified through a collaborative research effort with Endorecherche Inc. (Laval University) – an oral anti-estrogen being studied for breast cancer and a topical anti-androgen being studied for acne.

Major Research Facilities

As part of a long-term commitment to science and innovation, Schering-Plough provides its scientists with the most advanced technologies and facilities available, and a working environment that can support the research demands of tomorrow. Together, SPRI's researchers are charting Schering-Plough's course for the future, using science for human advantage.

Our primary research facilities are located in New Jersey and California, as follows:

The Drug Discovery Facility (DDF) in Kenilworth, N.J.

Located on Schering-Plough's 106-acre pharmaceutical headquarters campus, the $300 million state-of-the-art DDF is the largest pharmaceutical research structure in New Jersey and represents the single largest capital investment in Schering-Plough's history.

Process Development Facilities in Union, N.J.

Nearly 300 engineers, scientists and technicians work in laboratories, pilot plants, and clinical and commercial production facilities in both chemical and biotechnology process development research. Here, solutions are developed to address the challenging scientific issues related to transferring compounds from laboratory-scale to clinical- and commercial-scale manufacturing. Our researchers at Union have the use of:

• A new, state-of-the-art biotechnology pilot plant and production facility, opened in 1995.

• Chemical and biotechnology laboratories, pilot plants, and clinical- and commercial-scale production facilities used for synthesis, extraction, distillation, fermentation, separation and/or purification of compounds.

In addition, a new, state-of-the-art chemical development pilot plant facility is under construction and scheduled to open in early 1997.

The Pharmaceutical Development Facility (PDF) in Kenilworth, N.J.

At the PDF, Schering-Plough scientists devise formulations, drug delivery systems, packaging and manufacturing processes. Modern clinical production facilities, laboratories and a campus setting promote collaboration among the many scientists, engineers, and specialists needed to successfully develop and obtain approval for commercially-viable compounds.

The DNAX Research Institute in Palo Alto, California

DNAX is a biotechnology research facility where molecular and cell biologists and immunologists conduct pioneering research into regulating the immune system and preventing the initiation of the body's allergic responses. DNAX:

• Is located adjacent to the Stanford University campus, within an hour's drive of three other important centers for biochemistry and medical research -- the Universities of California at Berkeley, San Francisco and Santa Cruz.

• Utilizes the latest computer systems for scientific data acquisition and analysis.

• Maintains a professionally staffed library containing an extensive collection of scientific journals and access to on-line databases.

Canji, Inc., in San Diego, California

A leading gene therapy company, Canji was acquired by Schering-Plough in February 1996 and now serves as our research center for gene therapy -- a treatment approach holding significant scientific and medical potential for treating cancer and other diseases. Canji:

• Is located near Scripps Research Institute, the Salk Institute and the University of California, San Diego.

• Has 55 scientific positions and a small administrative staff.

• Maintains laboratories and offices occupying an area of 22,000 square feet on the second and third floors of a biotechnology complex which also houses Corvas and Alliance.

As an international organization, Schering-Plough Research Institute also provides research opportunities in diverse locations outside the U.S. Major research and clinical laboratories are located in France, Switzerland, Italy and Japan.